Kornimate/medical-research-clean huggingface dataset:
scale down for endometrial cancer

Conditions: Endometrial Cancer; Cancer of the Endometrium

Summary: this proposal will pilot a weight management program for patients with endometrial cancer, the cancer most associated with obesity. if successful, this pilot could be expanded to include obese women with other gynecologic cancers (ovarian and cervical) and could be expanded and adapted for use not only upon completion of treatment, but during chemotherapy or radiation. furthermore, other obstetricians and gynecologists could use this strategy for obese women as a practical cancer prevention strategy for obesity-associated cancers.


Eligibility criteria:
inclusion criteria: * female women 18 years of age or older and with biopsy-proven endometrial cancer. * bmi greater than or equal to 30 kg/m\^2. * must be able to read and speak english. * all patients must be informed of the investigational nature of this study and must sign and give written informed consent for aim 1 study activities in accordance with institutional and federal guidelines. * has completed prior surgical management and adjuvant endometrial cancer treatment, if adjuvant treatment is indicated, prior to starting aim 1. * is not receiving concurrent cytotoxic chemotherapy and/or radiation therapy at time of enrollment and, if randomized, is not anticipated that the participant will need to receive concurrent cytotoxic chemotherapy and/or radiation therapy at any time during the aim 1 intervention * patients with bmi greater than or equal to 30 kg/m\^2 who are undergoing hormonal treatment of endometrial cancer. * eastern cooperative oncology group (ecog) performance status 0-2 * life expectancy of at least one year * must have a phone capable of receiving text messages. exclusion criteria: * females under the age of 18 years * bmi less than 30 kg/m\^2 * must not be participating in another formal weight loss program. * must not have any other clinically significant medical disease or condition that, in the investigator's opinion, may interfere with protocol adherence or a participant's ability to give informed consent. * for participants who are randomized in aim 1: * no uncontrolled serious medical or psychiatric condition(s) that would affect the patient's ability to participate in the interventional study, e.g., uncontrolled hypertension, symptomatic cardiac disease, or severe/uncontrolled depression as indicated by a previously completed patient health questionnaire (phq-9) score \>9 (kroenke) * no diagnoses of any other invasive malignancy other than endometrial cancer or non-melanoma skin cancer which required active treatment currently or within the last 2 years.
comparison of mortality impact of coagulation rotative thromboelastometry analysis versus standard analysis

Conditions: Hemorrhage

Summary: digestive hemorrhage is a common cause of acute hemorrhage in france, and its mortality remains high despite improvement of endoscopy technique and therapeutics. hemostasis disorders are an important issue in the patient care both in severity diagnostic and therapeutic plan.

standard technique of coagulation analysis (prothrombin ratio, activated partial thromboplastin time, fibrinogen and platelet count) do not provide to guide practitioner in reanimation of hemostatic patients in particular when coagulation defect preexisting to the digestive hemorrhage. in this respect, the main objective of this study is to evaluate the interest of rotative thromboelastometry in the care of patient with digestive hemorrhage and its mortality impact.

Eligibility criteria:
inclusion criteria: * hospitalized patient in reanimation unit or continuous monitoring for digestive hemorrhage before or immediately after digestive endoscopy * digestive hemorrhage diagnostic: melena and/or rectal bleeding and/or hematemesis * affiliation to the social security * have signed an informed consent exclusion criteria: * pregnant or nursing woman * without digestive fibroscopy * with an anticoagulant treatment * with a congenital coagulopathy * decision of therapeutic limitation or moribund patient * with a digestive hemorrhage after an hospitalisation in reanimation unit for an other reason * participation in an other study in previous 30 days * under trusteeship, guardianship or judicial safeguards
novox®cup as primary dressing after breast reduction

Conditions: Wound Healing Disorder; Post-Surgical Complication; Mammaplasty

Summary: breast reduction is one of the most frequently performed plastic surgeries. studies have shown that breast reduction surgery significantly improves the patients' suffering and leads to a better health-related quality of life.however, as in every surgery, there can be complications. wound disorders, such as open wounds and skin loss account for the most commonly encountered postoperative complications. novox® cup is a new single-use wound dressing that is shaped cupular in order to tightly adapt to the breast anatomy. it is internally coated with oxygen-enriched oil releasing reactive oxygen species and is free from active pharmaceutical ingredients. it is intended, among other indications, for the use in surgical wounds after oncological breast surgery, breast reconstruction and cosmetic breast surgery. in two studies, a total of 140 patients (surgical wounds after breast augmentation-mastopexy, mammary lesions) were treated successfully with novox® cup and no product-related adverse events were reported.the claimed advantages sound promising but an advantage compared to established wound dressings such as sterile strips or tapes has still to be investigated. the aim of the following study is to compare the outcomes (postoperative complications, scar quality and patients' satisfaction) of breast reduction and application of the wound dressing novox® cup in comparison to already established wound closure systems 2 weeks and 3 months after surgery.

a prospective intra-individually controlled cohort study. one breast will be chosen (left or right) to be treated with the novox®-cup. the other breast will serve as the "standard of care" control. randomization within this clinical investigation will be done intra-individually in a 1:1 ratio.

Eligibility criteria:
inclusion criteria: * written informed consent * female patients 18 years and older * patient able to give informed consent * patients undergoing bilateral breast reduction exclusion criteria: * absent informed consent * patients from protected groups and those who are not personally able to give consent. * patients younger than 18 years * pregnancy (pregnancy test before enrollment) and breastfeeding women * former radiation of the breast(s) * former surgery at the operation site * skin abnormalities in the operation area (e.g. burn scars) * participation in other clinical trials during this study * active malignant disease * breast cancer history * radiation or chemotherapy during the study period or up to 6 months before possible enrollment * immune disease

Keywords: surgical wounds breast surgery plastic surgery oxygen-enriched oil dressing wound healing scar quality postoperative complications breast reduction
short term effects of prx-03140 in patients with mild alzheimer's disease being treated with aricept

Conditions: Alzheimer's Disease

Summary: this is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of prx-03140 administered orally once daily for 14 days in subjects with mild alzheimer's disease who are using a stable, well-tolerated 10 mg dose of aricept (donepezil) but continue to experience worsening ad symptoms.


Eligibility criteria:
inclusion criteria: * at least 60 years old. * on a stable 10 mg dose of aricept for at least 90 days and able to take it in the morning. * diagnosis of probable alzheimer's disease. * mild dementia. * you or your authorized representative provide voluntary written informed consent. * not pregnant, planning a pregnancy, or capable of becoming pregnant. exclusion criteria: * any other medical condition which, in the opinion of the investigator, would jeopardize your safety, impact the validity of the study results, or interfere with your ability to complete the study according to the protocol. * intolerance to aricept. * dementia other than alzheimer's type. * parkinson's disease. * history of seizure or epilepsy. * history of stroke. * participation in another research study within last 30 days. * enrollment in any previous research study testing prx-03140. * use of prescription cognitive enhancing medications (except aricept) or mao inhibitors within last 4 weeks. * use of tobacco products within last 4 weeks. * positive blood screen for hepatitis b surface antigen or hepatitis c antibody. * positive urine screen for alcohol or drugs of abuse or history of drug or alcohol abuse within last 6 months. * major surgery within last 4 weeks.

Keywords: alzheimer's disease ad prx-03140 dementia epix predix cognition enhancing
comparative study between ligasure versus conventional vessel ligation in thyroidectomy

Conditions: Thyroid Diseases

Summary: to compare between ligasure versus conventional vessel ligation in thyroidectomy as regards intraoperative and post operative complications rate

the significant vascularity of the thyroid gland and the relatively small operative field makes meticulous hemostasis an important prerequisite in thyroid surgery for successful outcome. the mainstay for achieving hemostasis in thyroidectomy is tying and / or clipping of blood vessels. new technologies have been introduced , among them the vessel sealing device ( ligasure ) which seals vessels by fusing the inner layers of the vessel wall with minimal levels of thermal dispersion burning and tissue friction thereby reducing incidence of accidental burns . this study is designed to evaluate the safety and efficacy of using ligasure compared with conventional vessel ligation in open thyroid surgery

Eligibility criteria:
inclusion criteria: * patient who will undergo lobectomy , subtotal thyroidectomy , total thyroidectomy at time of study * any age exclusion criteria: * patient undergoing re-do surgery " completion thyroidectomy " * patient undergoing concomitant procedures as cervical lymphadenectomy or parathyroidectomy

Keywords: thyroidectomy ligasure vessel ligation
reduction of postoperative pain after milligan-morgan haemorrhoidectomy with application of vitamin e ointment

Conditions: Pain

Summary: a prospective ranfomized clinical study of patients undergoing milligan morgan´s haemorrhoidectomy at hospital universitario rey juan carlos (móstoles-spain) will be performed. the patients will be randomized into 2 groups: * experimental group (eg): patients undergoing milligan morgan´s procedure and application of vitamin e ointment on the surgical bed. * control group (cg): patients undergoing milligan morgan´s procedure and application of vaseline on the surgical bed. postoperative pain determined by vas at the 1st, 3rd and 7th postoperative days, and need for morphine rescue will be investigated.

a prospective ranfomized clinical study of patients undergoing milligan morgan´s haemorrhoidectomy at hospital universitario rey juan carlos (móstoles-spain) will be performed. the patients will be randomized into 2 groups: * experimental group (eg): patients undergoing milligan morgan´s procedure and application of vitamin e ointment on the surgical bed. * control group (cg): patients undergoing milligan morgan´s procedure and application of vaseline on the surgical bed. postoperative pain determined by vas at the 1st, 3rd and 7th postoperative days, and need for morphine rescue will be investigated by a blined epidemiology nurse.

Eligibility criteria:
inclusion criteria: * patients undergoing milligan morgan´s haemorrhoidectomy at hospital universitario rey juan carlos (móstoles-spain). * haemorrhoids grade iii and iv * the patients sign an informed consent form agreeing their participation in the study. exclusion criteria: * patients undergoing other surgical techniques for haemorrhoidectomy, different tan milligan morgan * haemorrhoids grade i and ii * patients with medical or surgical pathologies that do not allow the participation in the study * disability to understand and accept the entry in the study
ovarian malignancy incidence in moderate risk women with low ca 125

Conditions: Ovarian Cancer

Summary: the investigators are assessing the incidence of ovarian cancer in premenopausal women who were at moderate risk of malignancy with low ca125.

about 10% of premenopausal women may have a surgery for ovarian masses. in premenopausal women the incidence of ovarian malignancy is 1:1000 in case of symptomatic ovarian cyst.1 ca125 is unreliable in differentiating benign from malignant ovarian mass in premenopausal women due to many false positive results and reduced specificity.1 pelvic vaginal ultrasonography is the most effective tool in evaluating ovarian masses due to increased sensitivity over abdominal us.1 an estimation of risk of malignancy index is essential in evaluating an ovarian mass.26 /2 risk of malignancy index combines presurgical features serum including ca125, menopausal status and ultrasound findings. rmi=ux mx ca125 in which each feature takes a score and after calculation score less than 25 is mild, from 25-250 moderate and more than 250 has a severe risk of malignancy needing oncologist.44/3

Eligibility criteria:
inclusion criteria: * women with complex ovarian cyst * abdominal pain * menometrorrhagia exclusion criteria: * significant weight loss * cachexia * history of ovarian or other malignancy * family history of ovarian cancer
medihoney® derma cream treatment for mild to moderate atopic dermatitis in children study

Conditions: Atopic Dermatitis

Summary: a randomized, open-label trial comparing medihoney derma cream to hydrocortisone 1% cream. children between the ages of 2-18 years old diagnosed with mild to moderate atopic dermatitis with an iga (investigator global assessment) score of 2-3, and a bsa (body surface area) score of 1%-10% were included.

a randomized trial comprising children aged 2-18 diagnosed with mild to moderate ad, with an iga of 2-3 and bsa of 1%-10%, including 30 patients, 20 using med-d-cream and 10 as controls using hydrocortisone 1% cream. patients applied creams for 2 weeks and were then followed for two weeks to measure clinical responses and pruritus change.

Eligibility criteria:
inclusion criteria: * 2-18 years old * mild to moderate atopic dermatitis * an iga score of 2-3 * bsa score of 1%-10%. exclusion criteria: * participation in any clinical trial less than 28 days before the enrollment * ad-related systemic therapy or phototherapy within 28 days prior to the enrollment * topical corticosteroids, calcineurin inhibitors, or pde4 inhibitors use within 7 days prior to the enrollment

Keywords: eczema atopic dermatitis medihoney dermacream
an integrated online program using psychoeducation and expressive writing for people with probable post-traumatic stress disorder and coexisting dissociative symptoms

Conditions: Stress Disorders, Post-Traumatic

Summary: objectives: to evaluate the feasibility, acceptability, safety, and preliminary effects of an integrated online program with psychoeducation and expressive writing components for people with probable post-traumatic stress disorder (ptsd) and coexisting dissociative symptoms. hypotheses to be tested: the program will be feasible, acceptable, and safe to participants. when compared with the waitlist control group, participants in the treatment group will report significantly lower ptsd symptom severity, lower dissociative symptom severity, and greater improvement on coping immediately post-intervention. design and subjects: an assessor-blind, two-arm, randomised waitlist-controlled pilot study is proposed; 90 community adults with significant ptsd and dissociative symptoms will be recruited. instruments: the ptsd checklist 5, dissociative experiences scale-taxon, and brief coping orientation to problems experienced inventory will be used. semi-structured interviews will be conducted for process evaluation. intervention: a 10-week integrated online program with psychoeducational and expressive writing components. main outcome measures: the primary outcome is ptsd symptom severity. the secondary outcomes are dissociative symptom severity and coping. the feasibility, acceptability, and safety of the program will also be examined. data analysis: feasibility and acceptability of the program will be assessed by examining the attrition rate, adherence rate, duration of subject recruitment, and post-program individual interviews. generalised estimating equations with covariate adjustments will be used to examine the preliminary effects of the program. expected results: adults in the community who experienced significant ptsd and dissociative symptoms will become more resourceful to cope with their traumatic experiences and show more improvements on ptsd and dissociative symptoms.


Eligibility criteria:
inclusion criteria: (a) be hong kong chinese residents between the ages of 18 and 65; (b) be able to read, write, and speak in chinese/cantonese; (c) meet the operational definitions of "probable ptsd" and "coexisting dissociative symptoms" in screening \[score ≥31 on the chinese version of the ptsd checklist 5 (pcl-5) and ≥20 on the chinese version of the dissociative experiences scale-taxon (des-t)\]; and (d) have access to a digital device with internet connectivity, such as a smartphone, tablet, or computer. exclusion criteria: (a) having participated in or currently receiving other psychoeducation/psychotherapies for ptsd or dissociative symptoms; (b) having clinically significant medical conditions that may interfere with safe study participation; (c) concurrent substance dependence, acute suicidality, psychosis, or gross cognitive impairment; and (d) visual, language, or communication difficulties.

Keywords: post-traumatic stress; dissociation; structured writing; pilot study
a cohort study of uterine malignancies

Conditions: Cervical Cancer; Endometrial Cancer

Summary: the purposes of current study were to explore the relationship between cervical cancer/endometrial cancer and demographic information, behavior and life style, pregnancy-related factors, and disease history, and to study the factors affecting the prognosis of cancers. in addition, omics tests were performed on the biological specimens to identify the diagnostic markers and prognostic biomarkers.

after being informed about the study and potential risks, all patients who meet the eligibility requirements will be enrolled.

Eligibility criteria:
inclusion criteria: * age 20-75 years; * women with cervical cancer or endometrial cancer with a definite pathological diagnosis for the first time; * women attending a health check-up; * obtain informed consent and sign an informed consent form. exclusion criteria: * patients who are unable to cooperate with the investigations such as mental disorders or cognitive impairment； * patients with cancer other than cervical cancer or endometrial cancer; * women who have received hysterectomy or pelvic radiation therapy previously.
effectiveness of combined anticoagulation and antithrombotic therapy vs antithrombotic therapy alone after lower extremity revascularization for peripheral arterial disease

Conditions: Combined Anticoagulation and Antithrombotic Therapy; PAD - Peripheral Arterial Disease

Summary: effectiveness of combined anticoagulation and antithrombotic therapy vs antithrombotic therapy alone after lower extremity revascularization for peripheral arterial disease.

anticoagulation and antithrombotic therapy is a crucial part of pad management as it prolongs the patecy of grafts in open surgical revascularization procedures so its proper dosage and duration without increasing risks to the patient and maximizing the benefits is very important. currently literature in pakistan regarding this problem couldn't be found so this study would help assessing the outcomes of anticoagulation and antithrombotic therapy in this population with respect to treatment options available and presentation variability of the peripheral arterial disease. patients with pad would be enrolled for 6 months and would be followed upto 12 months and then upto 24 months. eligible subjects will be randomized 1:1 to receive either rivaroxaban 5 mg twice daily plus aspirin 75 mg once daily or rivaroxaban-matching placebo twice daily plus aspirin 75 mg once daily stratified by type of procedure; the treatment assignment will be double-blinded. randomization and study treatment will begin as soon as possible but no later than 10 days after a successfull lower extremity revascularization. patients will be prohibited from taking any additional antithrombotic therapy other drugs, including anticoagulants, doses of aspirin \>100 mg daily, vorapaxar, ticagrelor, prasugrel, or cilostazol. enrolled subjects will be having symptomatic pad defined by evidence of an abnormal ankle-brachial index ≤0.80 in either limb with an anatomy of occlusive disease of involving segments. subjects would be randomized who had undergone a technically successful endovascular, hybrid, or surgical ler within 10 days and had achieved adequate hemostasis before randomization.

Eligibility criteria:
inclusion criteria: - all patients with pad candidates for revascularization procedures exclusion criteria: 1. planned long-term dual antiplatelet therapy (\>6 months), 2. clinical requirement for therapeutic anticoagulation, 3. recent acute limb ischemia or acute coronary syndrome, 4. medical condition that could increase the risk of major bleeding, significantly impaired renal function at baseline (estimated glomerular filtration rate \<15 ml•min-1•1.73 m-2), 5. any documented history of intracranial hemorrhage, stroke, or transient ischemic attack

Keywords: rivaroxaban in pad
long-term effects of family wish program for adolescents with congenital heart disease

Conditions: Heart Defects, Congenital

Summary: the goal of this clinical trial is to learn the long-term effects of "family walking instruction with support by heart" (family wish) on frailty state, quality of life and family functioning among adolescents with congenital heart disease (chd). researchers will compare the 12-week family wish program, based on self-efficacy theory, to a comparison group receiving a family walking health education sheet to evaluate the long-term effectiveness of the family wish program. participants will: * walk with family members for 20-30 minutes daily, at least 5 times per week, totaling 150 minutes per week. * keep a diary to record the frequency of their walks and any symptoms experienced. * complete questionnaires at baseline, and at 6, 12, and 24 weeks.


Eligibility criteria:
inclusion criteria: * being between 12 and 18 years old; * having received a diagnosis of chd by a physician before age 2; * having received a diagnosis of chd with new york heart association (nyha) functional class i, ii, or iii; * having parents or guardians who were able to communicate in mandarin, and being able to communicate in mandarin themselves; * not having cognitive impairments, and; * voluntarily signing informed consent forms. exclusion criteria: * undergoing heart transplant surgery within the past year; * receiving cardiac catheterization intervention or open-heart surgery within the past 6 months; * having chd with nyha functional class iv; and * having other congenital diseases